Drug intelligence / Profile preview

CDCS29

Development stage: Preclinical
Lead developer: Chipscreen NewWay Biosciences
Modality: Small Molecules

Overview

CDCS29 is a preclinical small molecule G protein-coupled receptor (GPCR) agonist being developed by Chipscreen NewWay, a subsidiary of Shenzhen Chipscreen Biosciences. The drug is currently under investigation for the treatment of obesity and other metabolic diseases. As a GPCR agonist, CDCS29 is designed to activate specific metabolic signaling pathways to regulate energy homeostasis and glucose metabolism. It is part of Chipscreen NewWay's innovative pipeline, which focuses on novel mechanisms of action for metabolic and inflammatory conditions.

Beyond the preview

Go deeper on CDCS29.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDCS29.

Explore the full profile